Page 124 - Vitamin D and Cancer

5 Vitamin D and Angiogenesis 111

SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an
experimental model of colon carcinoma. Clin Cancer Res 11:5827–5832
60. Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining
anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203–220
61. Frost P, Moatamed F, Hoang B, Shi Y, Gera J, Yan H, Frost P, Gibbons J, Lichtenstein A
(2004) In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple
myeloma cells in a xenograft model. Blood 104:4181–4187
62. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van
Waes C (2001) Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-
kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin
Cancer Res 7:1419–1428
63. Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39:1489–1499
64. Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic
cancer therapies against primary and metastatic disease. Cancer Res 52:6702–6704
65. Kakeji Y, Teicher BA (1997) Preclinical studies of the combination of angiogenic inhibitors
with cytotoxic agents. Invest New Drugs 15:39–48
66. Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as
antiangiogenics. J Clin Oncol 19:1195–1206
67. Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, Haussler MR,
Rauterberg EW, Ritz E (1989) Identification and regulation of 1, 25-dihydroxyvitamin D3
receptor activity and biosynthesis of 1, 25-dihydroxyvitamin D3. Studies in cultured
bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 83:1903–1915
68. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL (2002) Antiproliferative effects of
1alpha, 25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial
cells. Endocrinology 143:2508–2514
69. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL (2006) Differential antipro-
liferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer
Res 66:8565–8573
70. Merke J, Hofmann W, Goldschmidt D, Ritz E (1987) Demonstration of 1, 25(OH)2 vitamin D3
receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int 41:112–114
71. Koh E, Morimoto S, Fukuo K, Itoh K, Hironaka T, Shiraishi T, Onishi T, Kumahara Y (1988)
1, 25-Dihydroxyvitamin D3 binds specifically to rat vascular smooth muscle cells and stimu-
lates their proliferation in vitro. Life Sci 42:215–223
72. Mitsuhashi T, Morris RC Jr, Ives HE (1991) 1, 25-dihydroxyvitamin D3 modulates growth
of vascular smooth muscle cells. J Clin Invest 87:1889–1895
73. Cardus A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM (2006) 1,
25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a
VEGF-mediated pathway. Kidney Int 69:1377–1384
74. Rajasree S, Umashankar PR, Lal AV, Sarma PS, Kartha CC (2002) 1, 25-dihydroxyvitamin
D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci
70:1777–1788
75. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, Stewart PM,
Hewison M (2002) Synthesis of 1, 25-dihydroxyvitamin D(3) by human endothelial cells is
regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhe-
sion. J Am Soc Nephrol 13:621–629
76. Mantell DJ, Owen PE, Bundred NJ, Mawer EB, Canfield AE (2000) 1 alpha,
25- dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214–220
77. Albert DM, Scheef EA, Wang S, Mehraein F, Darjatmoko SR, Sorenson CM, Sheibani N
(2007) Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis
Sci 48:2327–2334
78. Chung I, Karpf AR, Muindi JR, Conroy JM, Nowak NJ, Johnson CS, Trump DL (2007)
Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective
growth inhibition by calcitriol. J Biol Chem 282:8704–8714